TITLE

Calcium not to be given with Rocephin

PUB. DATE
July 2007
SOURCE
Drug Topics;7/23/2007, Vol. 151 Issue 14, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that changes to Roche Laboratories Inc.'s ceftriaxone label for injection have been made following reports of calcium-ceftriaxone precipitates in the lungs and kidneys, leading to fatal reactions. The revised information has been added to the Contraindications, Warnings, Precautions, Adverse Reactions and Dosage and Administration sections of the prescribing information. It is recommended that hyperbilirubinemic neonates should not be treated with ceftriazone. It is also suggested that the drug must not be mixed or administered simultaneously or within 48 hours of calcium-containing solutions or products, even when different infusion lines are being used.
ACCESSION #
26131610

 

Related Articles

  • New brand name for Roche's IV flumazenil.  // Drug Topics;8/16/93, Vol. 137 Issue 16, p5 

    Reports on Roche Laboratories' change of a drug's name from Mazicon to Romazicon I.V. Possible confusion with Burroughs Wellcome Co.'s Mivacron.

  • New warning added to Fortvase labeling. Dickinson, James G. // Medical Marketing & Media;Apr2001, Vol. 36 Issue 4, p34 

    Reports on the addition of a warning on the labeling against the use of Fortovase by Hoffmann-LaRoche Inc. in the U.S.

  • Novel drug promotes weight loss, reduces obesity-related risks. Portyansky, Elena // Drug Topics;5/17/99, Vol. 143 Issue 9, p27 

    Focuses on Xenical, an antiobesity drug from Hoffmann-La Roche. Weight-loss benefits of orlistat; Side-effects of the drug; Information on minimizing the drug's side-effects. INSET: Tips to Remember.

  • New Accutane studies surface in wake of $70 million lawsuit against Roche. Troy, Timothy N. // Dermatology Times;Jun2002, Vol. 23 Issue 6, p6 

    Reports the initiation of a study on the association of Accutane from Hoffman-La Roche Inc. with causal trigger for depression and suicide in the U.S. Focus of the study; Amount of lawsuit alleged to La Roche; Views of Donald H. Marks, a clinical research expert on the adverse effects of Accutane.

  • Legal aid won for malaria drug case. Dyer, Clare // BMJ: British Medical Journal (International Edition);9/14/96, Vol. 313 Issue 7058, p643 

    Reports on the investigation of the effectiveness of the malarial drug mefloquine, which will serve as the basis of the Legal Aid Board's decision on the filing of a case against the drug manufacturer Hoffmann-La Roche Inc. Adverse effects of Lariam; Includes panic attacks; Depression and fits.

  • Shared responsibility for patient-directed information. Brushwood, David B. // Pharmacy Today;May2011, Vol. 17 Issue 5, p23 

    The article discusses the shared responsibility of drug manufacturers, pharmacists, and providers of electronic patient information monographs for patient-directed information on drugs in the U.S. Risk Evaluation and Mitigation Strategies (REMS) serves as basis for patient information on drugs...

  • New tetratol calcium antagonist indicated for treatment of hypertension, heart condition.  // Drug Store News;7/14/97, Vol. 19 Issue 11, pCP8 

    Introduces Hoffman-La Roche Inc.'s class of tetralol calcium antagonists Posicor, mibefradil dihydrochloride, for the treatment of hypertension and chronic angina pectoris.

  • Reports of Suicide, Depression Spark Acne Medication Labeling Change.  // Dermatology Times;Mar1998, Vol. 19 Issue 3, p12 

    Provides information on the plans of Hoffman-La Roche Incorporated to change the labeling of Accutane, a drug for severe, recalcitrant, nodular acne. Reason for the labeling changes; Association of acne with depression.

  • Clarithromycin: labelling change.  // WHO Drug Information;2001, Vol. 15 Issue 2, p80 

    Reports on the Japanese Ministry of Health, Labor and Welfare's call for hepatic dysfunction, jaundice and rhabdomyolysis to be included in the 'Clinically significant adverse reactions' section of clarithromycin-containing products Clarith and Klaricid for pediatric use. Number of reported...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics